N-[5-[(4-甲氧基苯基)甲基]-1,3,4-噻二唑-2-基]苯磺酰胺 | 519170-13-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[5-[(4-甲氧基苯基)甲基]-1,3,4-噻二唑-2-基]苯磺酰胺
• 英文名称: N-[5-(4-methoxybenzyl)-1,3,4-thiadiazol-2-yl]benzenesulfonamide
• 英文别名: OU749；N-[5-[(4-methoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]benzenesulfonamide
• CAS: 519170-13-9
• 化学式: C₁₆H₁₅N₃O₃S₂
• 分子量: 361.445
• InChiKey: QCXWBMZVLJCKHF-UHFFFAOYSA-N

物化性质

• 溶解度：
  二甲基亚砜：>20mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  对甲氧基苯乙酸 在 吡啶 、 三氯氧磷 作用下， 反应 4.75h， 生成 N-[5-[(4-甲氧基苯基)甲基]-1,3,4-噻二唑-2-基]苯磺酰胺
  参考文献：
  名称：

  Divergent effects of compounds on the hydrolysis and transpeptidation reactions of γ-glutamyl transpeptidase

  摘要：

  A novel class of inhibitors of the enzyme gamma-glutamyl transpeptidase (GGT) were evaluated. The analog OU749 was shown previously to be an uncompetitive inhibitor of the GGT transpeptidation reaction. The data in this study show that it is an equally potent uncompetitive inhibitor of the hydrolysis reaction, the primary reaction catalyzed by GGT in vivo. A series of structural analogs of OU749 were evaluated. For many of the analogs, the potency of the inhibition differed between the hydrolysis and transpeptidation reactions, providing insight into the malleability of the active site of the enzyme. Analogs with electron withdrawing groups on the benzosulfonamide ring, accelerated the hydrolysis reaction, but inhibited the transpeptidation reaction by competing with a dipeptide acceptor. Several of the OU749 analogs inhibited the transpeptidation reaction by slow onset kinetics, similar to acivicin. Further development of inhibitors of the GGT hydrolysis reaction is necessary to provide new therapeutic compounds.

  DOI：

  10.3109/14756366.2011.597748

文献信息

• Gamma-glutamyl transpeptidase inhibitors and methods of use
  申请人：The Board of Regents of the University of Oklahoma

  公开号：US09540337B2

  公开（公告）日：2017-01-10

  Compositions that are effective in inhibiting gamma-glutamyl transpeptidase are disclosed. Methods of producing and using these compositions are also disclosed.

  揭示了能有效抑制γ-谷氨酰转肽酶的组合物。同时还揭示了生产和使用这些组合物的方法。
• Coordinated metabolic reprogramming in response to productive viral infections
  申请人：ST. JUDE CHILDREN'S RESEARCH HOSPITAL

  公开号：US11083725B2

  公开（公告）日：2021-08-10

  The invention generally relates to methods of treating viral infections using known drugs and pharmaceutical compositions comprising same. More specifically, the disclosed methods are useful for the treatment of viral infections that are enveloped viruses. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明一般涉及使用已知药物和包含已知药物的药物组合物治疗病毒感染的方法。更具体地说，所公开的方法可用于治疗包膜病毒感染。本摘要旨在作为一种扫描工具，用于在特定技术领域进行搜索，而无意限制本发明。
• INHIBITION OF GAMMA-GLUTAMYLTRANSFERASE AND GLUTATHIONE CATABOLISM TO ENHANCE THE EFFICACY OF NF-KB SIGNALLING PATHWAY INHIBITORS
  申请人：Universität Heidelberg

  公开号：EP3624793A1

  公开（公告）日：2020-03-25
• GAMMA-GLUTAMYL TRANSPEPTIDASE INHIBITORS AND METHODS OF USE
  申请人：Hanigan Marie H.

  公开号：US20100197745A1

  公开（公告）日：2010-08-05

  The present invention enhances the effects of antitumor agents and increases the sensitivity of therapy-resistant tumor cells to antitumor agents such as chemotherapeutic agents and radiation. The present invention is thus directed to compositions and methods for inhibiting and killing neoplastic cancer cells, for example for the treatment, inhibition or prevention of tumors or malignant growths or other neoplasias in mammals. The GGT inhibitor compounds used in the methods of the present invention comprise a class of benzylthiadiazol benzenesulfoniamides represented by the general structure Formula (I) ( FIG. 1 ), or a pharmaceutically acceptable salt thereof, wherein any one or more of R 1 -R 10 may be H, Cl, F, Br, I, OH, an alkoxy, or NO 2 . Other R groups include carrier groups linked by C,N, or O. The present invention also provides a method for the prophylaxis or treatment of a reversible airways obstruction in a mammal, such as a human, comprising administration of a therapeutically effective amount of a GGT inhibitor described herein for the prophylaxis or treatment of a disease associated with reverse airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), allergic reaction, respiratory tract infection or upper respiratory tract disease. Other diseases or conditions which may be treated include, for example, degenerative diseases, renal diseases, liver diseases, and inner ear conditions or diseases.
• COORDINATED METABOLIC REPROGRAMMING IN RESPONSE TO PRODUCTIVE VIRAL INFECTIONS
  申请人：ST. JUDE CHILDREN'S RESEARCH HOSPITAL

  公开号：US20170304293A1

  公开（公告）日：2017-10-26

  The invention generally relates to methods of treating viral infections using known drugs and pharmaceutical compositions comprising same. More specifically, the disclosed methods are useful for the treatment of viral infections that are enveloped viruses. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.